Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.55 |
| ▸ | KDM5A | P29375 | 2/20 | 0.55 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.55 |
| ▸ | JMJD1C | Q15652 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM6B | O15054 | 1/20 | 0.47 |
| ▸ | TET3 | O43151 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.47 |
| ▸ | KDM5C | P41229 | 1/20 | 0.47 |
| ▸ | ASPH | Q12797 | 1/20 | 0.47 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.47 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.47 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.47 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590602 | 0.80 | ALDH1A1 (0.47) | KDM4EKDM5AKDM3AJMJD1CALDH1A1 | |
| SCHEMBL9953724 | 0.80 | PIM1 (0.43) | KDM4EKDM5AKDM3AJMJD1CTSHR | |
| Orotic Acid SCHEMBL9443769 | 0.79 | KDM4E (0.46) | KDM4EKDM5AKDM3AJMJD1CALOX15 | |
| SCHEMBL1505808 | 0.79 | KDM4E (0.57) | KDM4EKDM5AKDM3AJMJD1CALOX15 | |
| SCHEMBL31126262 | 0.77 | KDM4E (0.55) | KDM4EKDM5AKDM3AJMJD1CALOX15 | |
| SCHEMBL87765 | 0.77 | KDM4E (0.55) | KDM4EKDM5AKDM3AJMJD1CALOX15 | |
| SCHEMBL163233 | 0.77 | KDM4E (0.55) | KDM4EKDM5AKDM3AJMJD1CALOX15 | |
| SCHEMBL31347597 | 0.77 | KDM4A (0.44) | KDM4EKDM5AKDM3AJMJD1CALOX15 | |
| SCHEMBL6325352 | 0.77 | KDM4E (0.55) | KDM4EKDM5AKDM3AJMJD1CALOX15 | |
| SCHEMBL26987029 | 0.77 | KDM4A (0.44) | KDM4EKDM5AKDM3AJMJD1CALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087634-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4551570-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Dong-A ST Co., Ltd. (KR) | 2025-05-14 | — | — | EP | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| CN-119403798-A | Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | 东亚ST 株式会社 | 2025-02-07 | — | — | CN | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-114409643-B | Dichlorobenzene poly-substituted piperazine compound and preparation method and application thereof | 山东大学 | 2022-10-25 | — | — | CN | disclosed |
| CN-114409643-A | Dichlorobenzene polysubstituted piperazine compound and preparation method and application thereof | 山东大学 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022048631-A1 | COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-03-10 | — | — | WO | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-7674795-B2 | Fluorene derivatives, composition containing said derivatives and the use thereof | AVENTIS PHARMA SA (FR) | 2010-03-09 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
| CN-101203518-A | Novel fluorene derivatives, compositions containing same and uses thereof | AVENTIS PHARMA SA (FR) | 2008-06-18 | — | — | CN | disclosed |
| CN-1289490-C | Oxazole and thiazole derivatives as antidiabetic and antiobesity agents | BRISTOL MYERS SQUIBB CO (US) | 2006-12-13 | — | — | CN | disclosed |
| CN-1374955-A | Oxazole and thiazole derivatives as antidiabetic and antiobesity agents | BRISTOL MYERS SQUIBB CO (US) | 2002-10-16 | — | — | CN | disclosed |
| EP-0260057-A2 | 2-Oxo-4-carboxy-pyrimidines | THE UNIVERSITY OF MELBOURNE (AU) | 1988-03-16 | — | — | EP | disclosed |
| CN-85103724-A | The method for preparing novel pyrrolo-benzoglyoxaline | — | 1986-07-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | CYP11B2, NOS2, HMOX2 | KDM4E 1843/4885KDM5A 1231/4885KDM3A 1196/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | KDM4E 4591/4885KDM5A 4669/4885KDM3A 4592/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | KDM4E 4591/4885KDM5A 4669/4885KDM3A 4592/4885 |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | HSP90B1, HSP90AB1, HSP90AA1 | KDM4E 3419/4885KDM5A 4074/4885KDM3A 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.